Atomoxetine

Atomoxetine is prescribed to treat:

• Attention deficit hyperactivity disorder (adhd) • Various related conditions in the mental health category • Associated symptoms and complications

It is an important medication that helps manage these conditions effectively.

Atomoxetine (Strattera) is a non-stimulant used for attention-deficit/hyperactivity disorder in children, adolescents, and adults. It was the first non-stimulant approved for ADHD and remains the main alternative when a stimulant is unsuitable — though its effect is smaller and considerably slower to arrive, which shapes how it should be introduced.

Mechanism of Action

Atomoxetine selectively inhibits the presynaptic norepinephrine transporter, increasing norepinephrine availability. In the prefrontal cortex, where dopamine is also cleared largely by the norepinephrine transporter, this raises prefrontal dopamine as well — so despite acting on a single transporter, atomoxetine increases both catecholamines in the region most relevant to executive function.

Crucially, it does not raise dopamine in the nucleus accumbens, the reward pathway that mediates the reinforcing effects of stimulants. This is the mechanistic reason atomoxetine has no abuse potential and is not a controlled substance, and it is the single most important practical difference from methylphenidate and the amphetamines.

The trade-off is efficacy and speed. Effect sizes in ADHD are consistently smaller than with stimulants, and benefit accumulates over weeks rather than appearing on the first day. Full effect commonly takes six to twelve weeks, and partial effect at two to four weeks should not be read as failure.

That delay is the most common reason atomoxetine is abandoned prematurely. A family accustomed to the immediate response of a stimulant, or expecting one, frequently concludes after ten days that the drug does not work. Telling them at the outset that it will take two to three months, and that early absence of effect is expected, materially improves the chance of a fair trial.

Clinical Use

Atomoxetine is a reasonable choice where stimulants are not tolerated, where there is significant anxiety that stimulants worsen, where tics are prominent, where a controlled substance is undesirable — a history of substance use disorder, or a household where diversion is a concern — and where coverage is needed continuously through the day and evening rather than during school or working hours alone.

That last point is a genuine advantage. Because it is taken daily and works continuously rather than wearing off, atomoxetine covers evenings, homework, and weekends without a second dose or a rebound period. Families for whom the late-afternoon crash on a stimulant is the hardest part of the day sometimes prefer it despite the smaller average effect.

It is dosed once or twice daily, with weight-based dosing in children. Nausea and appetite suppression are common early and usually settle; taking it with food helps. Somnolence occurs in some patients and insomnia in others, so timing is individualised.

Among the non-stimulants, guanfacine ER and clonidine ER are alpha-2 agonists with a different profile — more sedating, useful for hyperactivity and impulsivity and for sleep, often used adjunctively with a stimulant. Viloxazine is a more recent non-stimulant option. The adult ADHD article covers the adult picture, and our psychiatric team manages treatment selection.

Monitoring and Follow-Up

Height, weight, heart rate, and blood pressure should be recorded at baseline and monitored, with growth tracked in children. Atomoxetine produces modest increases in heart rate and blood pressure similar to those seen with stimulants.

No routine laboratory monitoring is required, but atomoxetine carries a warning about rare hepatotoxicity. Liver enzymes are not checked routinely; instead, patients should be told to report jaundice, dark urine, right upper abdominal pain, or unexplained fatigue, and the drug is stopped and not restarted if liver injury is confirmed.

Atomoxetine is metabolised by CYP2D6, and poor metabolisers — roughly 7 percent of people of European ancestry — reach substantially higher levels. Strong CYP2D6 inhibitors including fluoxetine, paroxetine, and bupropion produce the same effect pharmacologically, which matters because these are commonly co-prescribed in patients with both ADHD and depression. Dose reduction is appropriate in these situations.

Response should be assessed with standardised rating scales at an adequate interval — not before six weeks, and ideally at three months. The MedlinePlus atomoxetine entry covers prescribing detail, and the CDC ADHD resource provides background on treatment options.

Special Populations

Atomoxetine carries a boxed warning about increased suicidal ideation in children and adolescents, identified in short-term trials. This warrants closer monitoring in the early weeks and after dose changes, particularly in younger patients, rather than avoidance.

In adults it is effective and its lack of controlled-substance status simplifies prescribing considerably, including for patients who travel or who find repeated in-person prescriptions burdensome. Hepatic impairment requires dose reduction; kidney impairment does not. It is contraindicated with MAO inhibitors and within 14 days of stopping one, and in narrow-angle glaucoma and pheochromocytoma. In pregnancy, data are limited and use is reserved for clear need.

Unlike stimulants, atomoxetine should not be stopped abruptly after prolonged use without discussion, though discontinuation symptoms are mild compared with many psychiatric medications.

Combination with a stimulant is used more often than the either-or framing suggests, particularly where a stimulant controls daytime symptoms well but coverage is needed into the evening, or where a lower stimulant dose is desirable. The two mechanisms are complementary rather than redundant.

When to Contact Your Doctor

Report yellowing of the skin or eyes, dark urine, right upper abdominal pain, unexplained nausea, or unusual fatigue — these suggest liver injury and warrant stopping the drug pending assessment.

Report new or worsening thoughts of self-harm, marked mood change, agitation, or unusual behaviour, particularly in a child or adolescent and particularly in the first weeks. Report rising blood pressure or a persistently rapid heart rate. Report significant appetite loss with weight loss, especially in a child.

If you have taken atomoxetine for less than two months and feel it is not working, raise it before stopping — that is within the expected window and stopping early is the most common reason a potentially effective treatment is abandoned.

To review your response, adjust the dose, or discuss whether a stimulant would suit you better, contact us or schedule a visit.